Resources
Business & Aids 2006
Forty million people are living with HIV, 4m became infected this year and nearly 3m died. Companies need to act now or face disastrous consequences.
Leader: Business & Aids - -
Content
INTRODUCTION: An ever wider gap
Treatment is at record levels but prevention is still a struggle, writes Andrew Jack
THE DRUG COMPANIES: A new mood of co-operation
Andrew Jack on a sector that is intensifying its distribution of drugs
FINANCE: In need of a new source of funds
Mobilising the private sector could help provide an important link, writes Andrew Jack
BIOTECHNOLOGY: Mission impossible?
Salamander Davoudi on the research costs standing in the way of development
SCIENTIFIC RESEARCH: A series of small advances
After years of disappointment, there is a sense of optimism about Aids vaccine development, writes Clive Cookson
DRUGS: The future is genetic
The market will grow to $10bn by 2015, yet only genes offer cure, writes Clive Cookson
SOUTH AFRICA: Shamed into action
’Lunatic fringe’ jibe has embarrassed the government, writes Caroline Southey
Peter Piot, guest columnist: Winning some fights but losing the battle
The Aids pandemic has caused the single greatest reversal to human development ever recorded.
INDIA: A threat to economic ambition
The government is calling for business involvement in a fight that has potential geo-strategic implications, writes Jo Johnson
RUSSIA: The trouble with a patriarchal society
The real struggle against HIV/Aids is a cultural one, writes Isabel Gorst
